Los Angeles, CA, United States of America

Eugenia Zah

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: **Eugenia Zah: A Pioneer in Chimeric Antigen Receptor Innovations**

Introduction

Eugenia Zah is an influential inventor based in Los Angeles, CA, who has significantly contributed to the field of biomedical innovations. With a remarkable portfolio of five patents, Zah is particularly noted for her groundbreaking work in developing chimeric antigen receptor (CAR) technologies, which have far-reaching implications in cellular therapy for various malignancies.

Latest Patents

Among her latest innovative contributions is the patented technology for a bispecific OR-gate chimeric antigen receptor responsive to CD20 and CD19. This novel CD20-OR-CD19 CAR protein construct offers a unique solution for the treatment of B cell malignancies, enabling T-cell activation through the detection of either CD19 or CD20, or both. The invention encompasses nucleic acids encoding the CAR and various methods of use, highlighting the significant therapeutic potential of engineered human T cells expressing this CAR.

Career Highlights

Throughout her career, Zah has collaborated with prestigious institutions, including the University of California and Seattle Children's Hospital. Her work in these environments has allowed her to further her research capabilities and translate innovative ideas into tangible therapeutic advancements.

Collaborations

Eugenia has closely worked with notable colleagues such as Yvonne Y Chen and Michael C Jensen, fostering an environment of collaboration that has driven her research forward. Their collective expertise has helped enhance the development and application of CAR technologies in clinical settings.

Conclusion

Eugenia Zah stands at the forefront of innovation in the field of chimeric antigen receptors, with her inventions reflecting a commitment to improving treatment options for B cell malignancies. Her work not only showcases her inventive prowess but also exemplifies the collaborative spirit necessary for advancing medical science. As the field of immunotherapy continues to evolve, Zah's contributions will undoubtedly remain influential, paving the way for future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…